

Kim A Margolin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4908279/kim-a-margolin-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

17,198
citations

57
h-index

130
g-index

206
ext. papers

19,934
ext. citations

7.4
avg, IF

6.13
L-index

#	Paper	IF	Citations
189	High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2105-16	2.2	1547
188	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1889-94	2.2	1425
187	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 908-18	21.7	1151
186	Sunitinib in patients with metastatic renal cell carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 2516-24	27.4	968
185	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 459-65	21.7	833
184	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016 , 374, 2542-52	59.2	828
183	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1430-7	2.2	735
182	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 722-730	59.2	659
181	Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 133-41	2.2	624
180	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology, The</i> , 2015 , 16, e270-8	21.7	472
179	Cytokines in cancer immunotherapy. <i>Cancers</i> , 2011 , 3, 3856-93	6.6	397
178	Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3743-8	2.2	346
177	Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. <i>Journal of Clinical Oncology</i> , 2001 , 19, 851-6	2.2	324
176	Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. <i>Journal of Clinical Oncology</i> , 2007 , 25, 247-56	2.2	256
175	Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3133-40	2.2	255
174	CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. <i>Cancer</i> , 2005 , 104, 1045-8	6.4	219
173	Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 56-67	5.1	203

172	Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4906-11	2.2	202
171	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 693-702	2.2	188
170	NCCN clinical practice guidelines in oncology: kidney cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 618-30	7.3	168
169	Sunitinib efficacy against advanced renal cell carcinoma. <i>Journal of Urology</i> , 2007 , 178, 1883-7	2.5	163
168	Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2178-84	2.2	161
167	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016 , 18, 1043-65	1	158
166	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 588-98	19.4	145
165	A phase II study of depsipeptide in refractory metastatic renal cell cancer. <i>Clinical Genitourinary Cancer</i> , 2006 , 5, 57-60	3.3	130
164	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. <i>Cell</i> , 2020 , 183, 347-362.e24	56.2	128
163	Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 4592-7	11.5	127
162	Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002 , 128, 214-8	4.9	122
161	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 561-8	12.9	114
160	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 37-45	7.5	106
159	Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2292-8	2.2	95
158	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology, The</i> , 2013 , 14, e396-406	21.7	92
157	Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group. <i>Blood</i> , 1997 , 90, 3844-3852	2.2	91
156	Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 5552-5561	12.9	89
155	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389	21.7	88

154	NCCN clinical practice guidelines in oncology: testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 672-93	7.3	87
153	Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. <i>Journal of Immunotherapy</i> , 2007 , 30, 762-72	5	83
152	Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy. <i>Blood</i> , 1999 , 93, 2788-2806	2.2	82
151	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group (E1687)	2.2	80
150	Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 19-26	3.5	80
149	Kidney cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 960-77	7.3	79
148	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 627-642	4.5	74
147	The treatment of brain metastases from malignant melanoma. <i>Seminars in Oncology</i> , 2002 , 29, 518-24	5.5	74
146	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. <i>Cancer</i> , 2008 , 113, 2139-45	6.4	70
145	A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 331-42	3.5	70
144	A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). <i>Cancer</i> , 2017 , 123, 2688-2697	6.4	69
143	Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). <i>Clinical Cancer Research</i> , 2012 , 18, 1129-37	12.9	68
142	Tumor-infiltrating lymphocytes in melanoma. <i>Current Oncology Reports</i> , 2012 , 14, 468-74	6.3	67
141	Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. <i>Cancer</i> , 2015 , 121, 432-440	6.4	66
140	T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3787-3795	2.2	66
139	Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. <i>Clinical Cancer Research</i> , 2011 , 17, 6574-81	12.9	65
138	Testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 502-35	7.3	64
137	Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. <i>Clinical Cancer Research</i> , 2004 , 10, 461-7	12.9	64

136	BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). <i>Journal of Clinical Oncology</i> , 2015 , 33, 2384-91	2.2	63
135	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology, The</i> , 2018 , 19, e20-e32	21.7	63
134	Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. <i>Investigational New Drugs</i> , 2001 , 19, 335-40	4.3	62
133	Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. <i>PLoS ONE</i> , 2012 , 7, e48787	3.7	60
132	Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. <i>Journal of Experimental Medicine</i> , 2016 , 213, 1133-9	16.6	55
131	Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2163-9	2.2	54
130	Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. <i>Journal of Immunotherapy</i> , 1994 , 15, 147-53	5	52
129	A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. <i>Investigational New Drugs</i> , 2012 , 30, 741-8	4.3	51
128	Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1839-48	2.2	49
127	Human breast tumor-infiltrating CD8 T cells retain polyfunctionality despite PD-1 expression. <i>Nature Communications</i> , 2018 , 9, 4297	17.4	48
126	Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin@ lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000 , 1, 46-54		46
125	Kidney cancer, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 175-82	7.3	43
124	Cellular immunotherapy and autologous transplantation for hematologic malignancy. <i>Immunological Reviews</i> , 1997 , 157, 231-40	11.3	42
123	NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9 Suppl 1, S1-29	7.3	41
122	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 2018 , 6, 44		39
121	Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. <i>Investigational New Drugs</i> , 1995 , 13, 157-62	4.3	39
120	High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. <i>Cancer</i> , 1994 , 73, 1678-85	6.4	39
119	Hepatic metastasis in granulosa cell tumor of the ovary. <i>Cancer</i> , 1985 , 56, 691-5	6.4	38

118	Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 3312-9	12.9	37
117	Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. <i>Medical Oncology</i> , 2001 , 18, 209-19	3.7	36
116	A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. <i>Cancer Journal (Sudbury, Mass)</i> , 2014 , 20, 18-24	2.2	35
115	Ipilimumab in a Phase II trial of melanoma patients with brain metastases. <i>Oncolimmunology</i> , 2012 , 1, 1197-1199	7.2	35
114	Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. <i>Investigational New Drugs</i> , 2005 , 23, 235-9	4.3	34
113	Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 778-85	4.7	33
112	Phase I study of mitomycin C and menadione in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 293-8	3.5	33
111	Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. <i>Cancer</i> , 2006 , 106, 2624-9	6.4	31
110	Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995 , 121, 103-6	4.9	31
109	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2016 , 17, 48	5.4	31
108	Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. <i>Clinical Cancer Research</i> , 2007 , 13, 1232-7	12.9	30
107	Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021 , 23, 356-375	1	28
106	Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. <i>Seminars in Oncology</i> , 2010 , 37, 468-72	5.5	27
105	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 1256-1264	12.4	27
104	High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. <i>Cancer</i> , 1994 , 73, 125-34	6.4	25
103	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017 , 23, 5034-5043	12.9	24
102	Inhibition of vascular endothelial growth factor in the treatment of solid tumors. <i>Current Oncology Reports</i> , 2002 , 4, 20-8	6.3	24
101	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021 , 23, 1961-1973	11.7	24

100	An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. <i>Cancer</i> , 2012 , 118, 4098-104	6.4	23
99	Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 903-11	4.7	23
98	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2021 , 22, 1692-1704	21.7	23
97	Management of Metastatic Melanoma in 2018. <i>JAMA Oncology</i> , 2018 , 4, 857-858	13.4	22
96	A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. <i>Journal of Immunotherapy</i> , 2013 , 36, 490-5	5	22
95	Multidisciplinary Approach to Brain Metastasis from Melanoma; Local Therapies for Central Nervous System Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 399-403	7.1	22
94	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 527-541	4.5	21
93	Cytokine therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 1495-505	5.4	21
92	Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 393-8	7.1	21
91	Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials. <i>Medical Oncology</i> , 2001 , 18, 197-207	3.7	20
90	Immune checkpoint blockade in patients with melanoma metastatic to the brain. <i>Seminars in Oncology</i> , 2015 , 42, 459-65	5.5	19
89	Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. <i>Gynecologic Oncology</i> , 2000 , 77, 433-8	4.9	18
88	Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 1999 , 5, 36-45	4.7	18
87	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , 7, 181-91	5.4	17
86	A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. <i>Journal of Immunotherapy</i> , 1995 , 18, 52-6	5	17
85	Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 399-403	7.1	16
84	Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1196-202	2.2	16
83	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2019 , 32, 458-469	4.5	15

82	Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 393-398	7.1	15
81	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019 , 125, 18-44	6.4	15
80	Methodologic guidelines for the design of high-dose chemotherapy regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 414-32	4.7	14
79	Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007 , 133, 705-11	4.9	13
78	Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. <i>Journal of Clinical Laboratory Analysis</i> , 2003 , 17, 184-94	3	13
77	State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal <i>Cancer</i> . <i>Cancer</i> , 2008 , 113, 1728-43	6.4	11
76	Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999 , 125, 292-6	4.9	11
75	The unique association of malignant histiocytosis and a primary gonadal germ cell tumor. <i>Medical and Pediatric Oncology</i> , 1992 , 20, 162-4		11
74	Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 2178	59.2	11
73	High dose chemotherapy and stem cell support in the treatment of germ cell cancer. <i>Journal of Urology</i> , 2003 , 169, 1229-33	2.5	10
72	Cytokine Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2019 , 33, 261-274	3.1	9
71	29th Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2015 , 3,		9
70	A phase II trial of gefitinib and pegylated IFN α in previously treated renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2011 , 16, 494-9	4.2	9
69	Inside life of melanoma cell signaling, molecular insights, and therapeutic targets. <i>Current Oncology Reports</i> , 2009 , 11, 405-11	6.3	9
68	Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 1149-55	3.5	9
67	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 811-22	7.3	9
66	Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 927-33	3.5	8
65	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 353-9	3.5	8

64	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47, 327-32	3.5	8
63	Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up. <i>Gynecologic Oncology</i> , 1999 , 75, 419-26	4.9	8
62	Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. <i>JAAD Case Reports</i> , 2020 , 6, 195-197	1.4	7
61	Introduction to the role of the immune system in melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 537-58	3.1	7
60	Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 121-7	3.3	7
59	Summary of the primer on tumor immunology and the biological therapy of cancer. <i>Journal of Translational Medicine</i> , 2009 , 7, 11	8.5	7
58	Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma. <i>Community Oncology</i> , 2008 , 5, 367-374		7
57	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 283-9	3.5	7
56	A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 403-10	3.5	7
55	High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide. <i>Cancer</i> , 1993 , 71, 2351-7	6.4	7
54	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, e59-e69	7.1	6
53	Hemorrhagic collision metastasis in a cerebral arteriovenous malformation. <i>Journal of NeuroInterventional Surgery</i> , 2015 , 7, e34	7.8	6
52	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 641-650	7.1	6
51	Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 241-8	3.5	6
50	Treatment of metastatic malignant melanoma with trimetrexate: a phase II study. <i>Medical and Pediatric Oncology</i> , 1990 , 18, 49-52		6
49	High-titer, high-thermal-amplitude cold autoagglutinin not associated with hemolytic anemia. <i>Vox Sanguinis</i> , 1988 , 55, 26-9	3.1	6
48	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. <i>Frontiers in Oncology</i> , 2019 , 9, 1483	5.3	6
47	Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. <i>ESMO Open</i> , 2021 , 6, 100252	6	6

46	BRAF inhibition and beyond in advanced melanoma. <i>Lancet, The</i> , 2012 , 380, 320-2	4.0	5
45	Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study. <i>Journal of Immunotherapy</i> , 2007 , 30, 839-46	5	5
44	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 641-650	7.1	5
43	NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018 , 124, 4332-4341	6.4	5
42	A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 549-57	3.5	4
41	Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 284-93	4.7	4
40	Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 35, 161-4	3.5	4
39	Effectiveness and safety of ipilimumab therapy in advanced melanoma: evidence from clinical practice sites in the US. <i>Journal of Community and Supportive Oncology</i> , 2015 , 13, 131-138		4
38	Ipilimumab in patients with melanoma and brain metastases [Authors Reply]. <i>Lancet Oncology, The</i> , 2012 , 13, e277-e278	21.7	3
37	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. <i>Expert Review of Dermatology</i> , 2013 , 8, 479-487		3
36	An introduction to foundation and industry-sponsored research: practical and ethical considerations. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 498-503	3.1	3
35	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 120-131	7.3	3
34	Pathologic complete response with radiation and vismodegib in a patient with advanced basal cell carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2021 , 14, 46	1.6	3
33	Treatment of advanced melanoma with immunological checkpoint block. <i>Current Oncology Reports</i> , 2011 , 13, 430-2	6.3	2
32	Interleukin-2 as Cancer Therapy 2006 , 355-364		2
31	Autologous and allogeneic high-dose therapy for melanoma. <i>Current Oncology Reports</i> , 2001 , 3, 338-43	6.3	2
30	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. <i>Blood</i> , 2004 , 104, 810-810	2.2	2
29	Brain Metastases in Melanoma: Moving Toward Curing the Incurable. <i>Journal of Oncology Practice</i> , 2016 , 12, 545-6	3.1	2

28	What is new on the horizon in melanoma brain metastasis?. <i>ESMO Open</i> , 2019 , 4, e000579	6	2
27	Fulminant Disseminated Intravascular Coagulation as Initial Presentation of BRAF-Mutated Melanoma. <i>Case Reports in Oncological Medicine</i> , 2019 , 2019, 9246596	0.9	1
26	Hemorrhagic collision metastasis in a cerebral arteriovenous malformation. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	1
25	Adoptive T-cell therapy of melanoma using designer T-cell receptors. <i>Current Oncology Reports</i> , 2011 , 13, 427-9	6.3	1
24	Indoor tanning use among U.S. youth--can skin health behaviors be legislated?. <i>Current Oncology Reports</i> , 2010 , 12, 290-1	6.3	1
23	Shortening the infusion time of anticancer drugs: who will benefit?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2642-3	2.2	1
22	Management of advanced germ cell cancer in patients with unfavorable prognosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005 , 3, 77-83	7.3	1
21	Phase I study of mitomycin C and menadione in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 293-298	3.5	1
20	Interleukin-2 and Cancer Therapy 2007 , 307-316		1
19	Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5240-5247	3.1	1
18	Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. <i>SAGE Open Medical Case Reports</i> , 2021 , 9, 2050313X211042215	9.7	1
17	Mitotic rate and younger age as predictors of sentinel lymph node positivity. <i>Current Oncology Reports</i> , 2005 , 7, 375, 376	6.3	1
16	Metabolic Checkpoint of Immune Cells in Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019 , 9, 581-583	4.4	0
15	Reply to A. Shinde et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1031-1032	2.2	
14	Cytokines in the Treatment of Cancer 2013 , 173-210		
13	Medical Management of Melanoma 2014 , 651-660		
12	IL-2 in the therapy of melanoma and other malignancies. <i>Medical Oncology</i> , 2009 , 26, 23-31	3.7	
11	CCR9:CCL25 in melanoma metastatic to small intestine. <i>Current Oncology Reports</i> , 2009 , 11, 331-2	6.3	

- 10 Control of experimental melanoma by host CXCR2. *Current Oncology Reports*, **2009**, 11, 333-4 6.3
- 9 Indoor tanning and substance-related disorder--related behaviors with similar treatment?. *Current Oncology Reports*, **2010**, 12, 288-9 6.3
- 8 Immunotherapy of Colorectal Cancer. *BioDrugs*, **1994**, 2, 42-52
- 7 Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy **2020**, 1421-1454
- 6 Melanoma and Other Cutaneous Malignancies **2008**, 2037-2059
- 5 Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy **2019**, 1-34
- 4 Targeting the mTOR, PI3K, and AKT Pathways in Melanoma **2012**, 107-123
- 3 Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade: How Much Is Enough?. *JAMA Oncology*, **2016**, 2, 1186-7 13.4
- 2 And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, 1-12 7.1
- 1 Molecular staging in stage II and III melanoma patients. *Current Oncology Reports*, **2005**, 7, 376 6.3